Aaron D. Goldberg

7.2k total citations · 1 hit paper
77 papers, 3.3k citations indexed

About

Aaron D. Goldberg is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Aaron D. Goldberg has authored 77 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 34 papers in Molecular Biology and 15 papers in Genetics. Recurrent topics in Aaron D. Goldberg's work include Acute Myeloid Leukemia Research (55 papers), Histone Deacetylase Inhibitors Research (18 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Aaron D. Goldberg is often cited by papers focused on Acute Myeloid Leukemia Research (55 papers), Histone Deacetylase Inhibitors Research (18 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Aaron D. Goldberg collaborates with scholars based in United States, Canada and Germany. Aaron D. Goldberg's co-authors include C. David Allis, Emily Bernstein, Robert F. Padera, Ron Blankstein, Maximilian Stahl, Simon J. Elsaesser, Bahram Razani, Bert W. O’Malley, Martin S. Tallman and Rainer B. Lanz and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Aaron D. Goldberg

69 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epigenetics: A Landscape Takes Shape

2007 1.7k citations Aaron D. Goldberg, C. David Allis et al. Cell profile →

Peers

Aaron D. Goldberg

HEMAT

ONCOL

GENET

Pierluigi Strippoli Italy

Eun Young Song South Korea

Jason N. Berman Canada

David J. Curtis Australia

Nicholas C. Wong Australia

Jens Vilstrup Johansen Denmark

Andrea Angius Italy

Daniela S. Gerhard United States

David Millar United Kingdom

Steven A. Schichman United States

Pierluigi Strippoli Italy

Aaron D. Goldberg

1.5k ×0.7

259 ×0.4

HEMAT

289 ×0.6

ONCOL

355 ×0.9

GENET

315 ×0.9

Citations per year, relative to Aaron D. Goldberg Aaron D. Goldberg (= 1×) peers Pierluigi Strippoli

Countries citing papers authored by Aaron D. Goldberg

Since Specialization

Citations

This map shows the geographic impact of Aaron D. Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron D. Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron D. Goldberg more than expected).

Fields of papers citing papers by Aaron D. Goldberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron D. Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron D. Goldberg. The network helps show where Aaron D. Goldberg may publish in the future.

Co-authorship network of co-authors of Aaron D. Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron D. Goldberg. A scholar is included among the top collaborators of Aaron D. Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron D. Goldberg. Aaron D. Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chin, Kuo‐Kai, Brian Ball, Yasmin Abaza, et al.. (2025). Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. Blood Advances. 10(5). 1537–1547.

Derkach, Andriy, Justin C. Wheat, Christopher Famulare, et al.. (2025). AML-1357: Outcomes in Acute Myeloid Leukemia With MECOM Rearrangement (MECOMr-AML) Treated With Hypomethylating Agent Plus Venetoclax. Clinical Lymphoma Myeloma & Leukemia. 25. S503–S503. 1 indexed citations

Chin, Kuo‐Kai, Yannis K. Valtis, Andriy Derkach, et al.. (2024). Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia. PubMed. 1(4). 100038–100038. 3 indexed citations

Chin, Kuo‐Kai, Andriy Derkach, Christopher Famulare, et al.. (2024). HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML. Leukemia & lymphoma. 66(2). 270–278.

Shimony, Shai, Jan Philipp Bewersdorf, Rory M. Shallis, et al.. (2024). Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 38(4). 762–768. 17 indexed citations

Wang, Eunice S., Aaron D. Goldberg, Martin S. Tallman, et al.. (2024). Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. Journal of Clinical Oncology. 42(15). 1776–1787. 22 indexed citations

Ravandi‐Kashani, Farhad, Aaron D. Goldberg, Elie Traer, et al.. (2023). PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES. Hematological Oncology. 41(S2). 834–835. 2 indexed citations

Badar, Talha, Ehab Atallah, Rory M. Shallis, et al.. (2023). Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 37(4). 799–806. 29 indexed citations

Robinson, Troy M., Robert L. Bowman, Ying Liu, et al.. (2023). Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Science Advances. 9(38). eadg0488–eadg0488. 24 indexed citations

10.

Badar, Talha, Mark R. Litzow, Rory M. Shallis, et al.. (2022). Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer. 129(6). 934–945. 5 indexed citations

11.

Prébet, Thomas, Aaron D. Goldberg, Joseph G. Jurcic, et al.. (2022). A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & lymphoma. 63(9). 2180–2188. 6 indexed citations

12.

Stahl, Maximilian, Kamal Menghrajani, Andriy Derkach, et al.. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. 5(5). 1552–1564. 108 indexed citations

13.

Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2020). Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research. 93. 106367–106367. 13 indexed citations

14.

Smith, Eric L., Sham Mailankody, Mette Stæhr, et al.. (2019). BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research. 7(7). 1047–1053. 67 indexed citations

15.

Goldberg, Aaron D., Chetasi Talati, Pinkal Desai, et al.. (2018). TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 1433–1433. 35 indexed citations

16.

Goldberg, Aaron D., Martin S. Tallman, Melhem Solh, et al.. (2017). Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia. Blood. 130. 2662–2662. 8 indexed citations

17.

Goldberg, Aaron D., Troy Z. Horvat, Meier Hsu, et al.. (2017). Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies. Blood. 130. 1353–1353. 18 indexed citations

18.

Banaszynski, Laura A., Duancheng Wen, Scott Dewell, et al.. (2013). Hira-Dependent Histone H3.3 Deposition Facilitates PRC2 Recruitment at Developmental Loci in ES Cells. Cell. 155(1). 107–120. 209 indexed citations

19.

Goldberg, Aaron D., C. David Allis, & Emily Bernstein. (2007). Epigenetics: A Landscape Takes Shape. Cell. 128(4). 635–638. 1712 indexed citations breakdown →

20.

Yang, Runying, Ali McBride, Yue-xian Hou, Aaron D. Goldberg, & Xiu-Bao Chang. (2005). Nucleotide dissociation from NBD1 promotes solute transport by MRP1. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1668(2). 248–261. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact